Lindsey Shapiro, PhD, science writer —

A Phase 1/2a clinical trial evaluating TED-A9, a human stem cell-based therapy, in people with Parkinson’s disease has finished dosing with no safety concerns identified to date. The therapy, delivered as a cell transplant directly into the brain, was given successfully to 12 adults diagnosed with Parkinson’s…

Visual and auditory cues delivered via an augmented reality (AR) headset were found to be feasible for adjusting gait among healthy young adults in a small recent study. Cues like the ones provided in the study have been proposed for improving gait in people with Parkinson’s disease, however, many…

Treatment with CNM-Au8, an investigational gold nanocrystal suspension therapy, boosted energy production in the brains of people with Parkinson’s disease and multiple sclerosis (MS) in a pair of Phase 2 trials, indicating the medication works as intended. Findings also suggest functional gains in treated Parkinson’s patients. However,…

Men with Parkinson’s disease exhibit more signs of accelerated brain aging than do women with the neurodegenerative condition, according to a new analysis that, its researchers say, bolsters the existing idea that a person’s sex plays a key role in Parkinson’s risk and progression. These findings were established by…

A Phase 2b trial testing the ability of IRLAB Therapeutics’ investigational oral therapy pirepemat to reduce falls in people with Parkinson’s disease is now expected to complete enrollment by September. Recruitment began last May and was initially expected to finish by the end of 2023, but the…

A new dual-target, adaptive deep brain stimulation (DBS) protocol may offer more clinical benefits for patients than does traditional DBS for Parkinson’s disease, according to newly published data from a small clinical trial. DBS surgery — in which a small device is implanted in the brain to deliver…

Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…

Produodopa (foslevodopa/foscarbidopa), AbbVie‘s continuous under-the-skin (subcutaneous) infusion formulation of levodopa/carbidopa, now is available in the European Union (EU) for advanced Parkinson’s disease patients whose severe motor fluctuations and involuntary movements are not controlled well with standard therapies. AbbVie initially was granted marketing authorization for Produodopa — also known…

A three-month exercise program focusing on Brazilian dance led to greater gains in lower limb strength among Parkinson’s disease patients than Nordic walking or deep-water exercise programs, according to a clinical trial report. Most measures of motor performance, cognitive function, and quality of life were unaltered by any of…

Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a sustained control of symptoms for Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from the nine-month extension study (NCT03877510) indicate dose adjustments and side effects were…